



December 22, 2023

Company name: LinqMed Inc.
Representative: Yukie Yoshii

LinqMed selected by NEDO to receive award from the Deep-Tech Startup Support Program

CHIBA, JAPAN – December 22th, 2023 –LinqMed Inc. (CEO Yukie Yoshii, Headquarters: Chiba-shi, Chiba, Japan, “LinqMed”), a radiopharmaceutical company focusing on the development of innovative “visible” anti-cancer therapeutics to patients, announced that LinqMed has been selected by NEDO (New Energy and Industrial Technology Development Organization) to receive support from the Deep-Tech Startup Support Fund/Deep-Tech Startup Support Program. This project will receive up to 1 billion yen in grants from NEDO as part of the PCA phase.


Project name: Development of the ^{64}Cu -based drug discovery platform for generating innovative pharmaceuticals

Phase: Product Commercialization Alliance (PCA)


Project period: Until March 2026

Research funding granted: up to 1 billion yen

Business purpose: In this NEDO-supported project, LinqMed will develop innovative technology platform for larger scale manufacturing of ^{64}Cu . ^{64}Cu has some unique characteristics such as (1) emitting radiation for diagnostic and therapeutic purposes and (2) easily binding to a variety of molecules. This platform will enable Japanese and global drug industries to rapidly discover a series of new "visible" anti-cancer therapeutics to help the patients with life-threatening diseases. ^{64}Cu -based next-generation drugs from this platform will create a new industrial basis.



Conventional radiotherapy and chemotherapy for cancer have some limitations such as insufficient therapeutic effects and significant side effects on healthy cells. On the other hand, we have developed a radiopharmaceutical employing copper radioisotope, ^{64}Cu , which can overcome these problems. In addition to the beta particles used in conventional radiotherapeutics, ^{64}Cu emits a unique radiation called Auger electron, which enables us to treat cancer cells effectively with high energy. Moreover, as ^{64}Cu is a positron-emitting isotope, it allows us to proceed with treatments while noninvasively and simultaneously visualize the drug accumulation to the disease sites using Positron Emission Tomography (PET) imaging.



Furthermore, ⁶⁴Cu can be conjugated with various molecules that have high binding affinity to cancer cells. This enables us to sustainably create a wide variety of anti-cancer drugs. By using ⁶⁴Cu's unique features, we are aiming to implement "Innovative 'Visible' Cancer Treatment" to our society. With the goal to establish a ⁶⁴Cu-based drug discovery platform and create a new industry, the funds raised through the Series A, together with the award from NEDO will be used to install a cyclotron and build drug manufacturing facilities necessary for large-scale capabilities to produce radiopharmaceuticals using ⁶⁴Cu in Japan.

NEDO 「Deep-Tech Startup Support Project」

"Deep-Tech Startup Support Program" provides support for research and development and commercialization in three phases for "deep-tech startups" engaged in research and development of innovative technologies. Eligible projects are those that require long-term research and development and large-scale funding to establish the technology, commercialize it, and implement it in society and that are considered to contribute to solving economic and social issues (carbon neutrality, resource circulation, economic security, etc.) to be addressed by the country or the world as a whole, despite the high risk involved.

Business overview page :

URL : https://www.nedo.go.jp/english/activities/activities_ZZJP_100250.html

Adoption results publication page :

URL : https://www.nedo.go.jp/koubo/CA3_100419.html (Japanese Only)

About LinqMed Inc.

LinqMed Inc. is an R&D start-up company developing radiopharmaceuticals to provide innovative "visible" anti-cancer treatments to patients. Our mission is "Link for Life - Linking Innovative Science and Medicine for Your Health and Happiness". LinqMed Inc. has been launched as a certified venture company of the National Institutes for Quantum Sciences and Technology (QST). We are developing radiopharmaceuticals using a copper radioisotope ⁶⁴Cu, which can be used for diagnosis and therapy, simultaneously. For more information, please visit our website at <https://www.linqmed.co.jp/>.

Inquiries:

LinqMed Inc.

Email: linqmed@linqmed.co.jp